liposarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature.
|
31798393 |
2019 |
liposarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, these profiles did not segregate by histology (lung adenocarcinoma-appendiceal cancer (KRAS G12D and GNAS R201C), and lung adenocarcinoma-liposarcoma (CDK4 and MDM2 amplification pairs)).
|
26418953 |
2015 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, MLPA proves to be an appropriate and straightforward technique for screening MDM2/CDK4 amplification in lipomatous tumors, especially when a correct cut-off value and reference samples are chosen, and could be considered a good alternative to FISH to determine MDM2 and CDK4 amplification in liposarcomas.
|
25679065 |
2015 |
liposarcoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CDK4/6 inhibitors have antiproliferative activity in CDK4-amplified liposarcoma and neuroblastoma, suggesting CDK4/6 inhibition as a potential therapeutic strategy in fusion-positive RMS.
|
25810375 |
2015 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Q-PCR analysis of the liposarcomas revealed the presence of CDK4 amplification in 44 cases (91.7%) and MDM2 amplification in 46 cases (95.8%).
|
25121597 |
2014 |
liposarcoma
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
|
23569312 |
2013 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
|
23569312 |
2013 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings indicate that analysis of FRS2 in combination with CDK4 and MDM2 will more accurately characterize pathologic features of high-grade liposarcomas.
|
23393200 |
2013 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We demonstrate that an alteration in the CDKN2A/CDKN2B/CDK4/CCND1 pathway is present in almost all cases without CDK4 amplification, thereby confirming the pivotal role of this pathway in liposarcoma oncogenesis.
|
21910158 |
2011 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
All of the liposarcomas had 12q13-q15 amplifications with varying peaks at CDK4 (12q14.1), HMGA2 (12q14.3), and MDM2 (12q15); 24% of the DDLS and no WDLS had 1p32.2 (JUN) amplifications; 33% WDLS and 35% DDLS had 1q24.3 amplifications involving DNM3 and miR-214/miR-199a2; 24% of the liposarcomas had 6q23-q24 amplifications (including MAP3K5).
|
21117066 |
2011 |
liposarcoma
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
|
20601955 |
2010 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
|
20601955 |
2010 |
liposarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The well-differentiated and dedifferentiated family of liposarcomas demonstrates amplification of the chromosome subregion 12q13-q15 with resultant amplification of the MDM2 and CDK4 genes.
|
19734852 |
2009 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma.
|
19626636 |
2009 |
liposarcoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
|
17214366 |
2007 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
An analysis of MDM2 and CDK4 amplification using real-time PCR, as well as FISH, is useful for the differential diagnosis of liposarcomas and their histologic mimickers.
|
16938516 |
2006 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Real-time PCR proved to be a fast and reliable method to characterize lipomas and liposarcomas by quantification of MDM2 and CDK4 gene amplification.
|
14694526 |
2004 |
liposarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As well as confirming the synergistic effect of MDM2 and CDK4, these results are consistent with the concept that amplicon(s) excluding MDM2 may contribute to transformation and support a role of CDK4 in opposing p53 function, particularly in NR WD liposarcoma.
|
9713346 |
1998 |
liposarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Both cellular flanking probes are outside the amplicon of this chromosome region identified in the OSA and RMS13 sarcoma cell lines, comprising SAS-CHOP-CDK4-MDM2 genes and where translocation breakpoints are located in liposarcomas.
|
7592643 |
1995 |
liposarcoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
liposarcoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|